INOZYME PHARMA INC. -
5.2234
08-October-24 12:35:35
15 minutes delayed
Stocks
+0.0034
+0.07%
Today's range
5.2200 - 5.4552
ISIN
N/A
Source
NASDAQ
-
09 Jun 2021 07:30:00 By Nasdaq GlobeNewswire
-
Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights
12 May 2021 06:00:00 By Nasdaq GlobeNewswire
-
07 May 2021 07:30:00 By Nasdaq GlobeNewswire
-
Inozyme Pharma to Present at the BofA Securities 2021 Virtual Healthcare Conference
06 May 2021 07:30:01 By Nasdaq GlobeNewswire
-
Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency
29 Apr 2021 07:30:00 By Nasdaq GlobeNewswire
-
Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting
08 Apr 2021 07:30:00 By Nasdaq GlobeNewswire
-
Inozyme Pharma Expands its Scientific Advisory Board
01 Apr 2021 07:30:00 By Nasdaq GlobeNewswire
-
Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights
25 Mar 2021 06:00:00 By Nasdaq GlobeNewswire
-
The Balancing Act® on Lifetime to Feature ENPP1 Deficiency
11 Mar 2021 07:30:00 By Nasdaq GlobeNewswire
-
Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer
04 Feb 2021 06:00:00 By Nasdaq GlobeNewswire
-
04 Jan 2021 06:00:00 By Nasdaq GlobeNewswire